Boston Scientific Corp (BSX)

Currency in USD
43.50
-0.82(-1.85%)
Closed·
40.19-3.31(-7.61%)
·
Unusual Post-Market activity
BSX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
43.2144.62
52 wk Range
39.57105.65
Key Statistics
Prev. Close
44.32
Open
43.87
Day's Range
43.21-44.62
52 wk Range
39.57-105.65
Volume
17.85M
Average Volume (3m)
19.61M
1-Year Change
-55.8779%
Book Value / Share
17.20
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BSX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
49.60
Upside
+14.02%
Members' Sentiments
Bearish
Bullish
ProTips
22 analysts have revised their earnings downwards for the upcoming period

Boston Scientific Corp News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Strong Sell

Analyst Ratings

20 Buy
11 Hold
0 Sell
Ratings:
31 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 49.60
(+14.02% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Barclays
Hold45.00+3.45%48.00Maintain30-10-2026
Oppenheimer
Hold---Downgrade29-10-2026
TD Cowen
Hold46.00+5.75%56.00Downgrade29-10-2026
Truist Securities
Buy51.00+17.24%-Maintain29-10-2026
Bernstein SocGen Group
Buy49.00+12.64%54.00Maintain29-10-2026

Boston Scientific Corp SWOT Analysis


Market Dominance
Boston Scientific's impressive 21.44% revenue growth and 20% organic growth highlight its strong market position and effective growth strategies
Strategic Acquisitions
Explore BSX's expansion into high-growth areas like renal denervation and neuromodulation through strategic acquisitions of SoniVie and Axonics
Analyst Optimism
With a consensus recommendation of 1.36, analysts project significant margin expansion and a weighted average market growth rate of 8.5% for 2025
Navigating Challenges
Delve into BSX's strategy to overcome tariff impacts and the TAVR exit, while leveraging its robust R&D capabilities to drive future innovations
Read full SWOT analysis

Boston Scientific Corp Earnings Call Summary for Q3/2026

  • Boston Scientific Q3 adjusted EPS of $0.73 missed $0.75 estimate; revenue of $5.14B slightly beat forecasts; stock fell 7.9% to $41.50
  • Cybersecurity incident cut organic growth to 1.5% vs 3-5% target, reducing EPS by $0.07 and sales by ~$150M; gross margin down 300bps YoY
  • Company expects 2027 to be trough year with continued pressure from WATCHMAN, EP competition, and China pricing erosion before 2028 recovery
  • Full-year 2026 guidance: organic growth ~3.75%, adjusted EPS $3.16-$3.18 (3-4% growth), operating margin ~27.6%, free cash flow ~$3.6B
  • Q4 outlook projects revenue down 3% to flat YoY, adjusted EPS $0.77-$0.79 with $0.04-$0.05 remaining cyber impact; new product launches delayed
Last Updated: 28-10-2026, 06:54 pm
Read Full Transcript

Earnings

Latest Release
28-10-2026
EPS / Forecast
0.73 / 0.75
Revenue / Forecast
5.14B / 5.12B
EPS Revisions
Last 90 days

BSX Income Statement

Compare BSX to Peers and Sector

Metrics to compare
BSX
Peers
Sector
Relationship
P/E Ratio
18.0x29.9x−0.2x
PEG Ratio
0.69−1.310.00
Price/Book
2.5x2.5x2.6x
Price / LTM Sales
3.0x2.0x2.8x
Upside (Analyst Target)
14.0%13.3%65.5%
Fair Value Upside
Unlock34.0%8.9%Unlock

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
728.70M50.28%32.30B
Other Institutional Investors
629.88M43.46%27.92B
Public Companies & Retail Investors
90.65M6.25%4.02B
Total
1.45B100.00%64.23B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BlackRock, Inc.8.95%12,96,80,91657,47,458
Vanguard Capital Management, LLC7.28%10,54,32,98146,72,790

FAQ

What Is the Boston Scientific (BSX) Share Price Today?

The Boston Scientific share price today is 43.50.

What is the current Boston Scientific (BSX) share price and day range?

As of 03-11-2026, the Boston Scientific share price is 43.50, with a previous close of 44.32. The share price has ranged from 43.21 to 44.62 today, while the 52-week range spans from 39.57 to 105.65.

What Is the Boston Scientific Market Cap?

As of today, Boston Scientific market cap is 63.10B.

What Is the Boston Scientific (BSX) Share Price Target?

The average 12-month share price target for Boston Scientific is 49.60, with a high estimate of 60 and a low estimate of 41. 20 analysts recommend buying, while 0 suggest selling, with an overall rating of Buy and +14.02% Upside potential.

What Is Boston Scientific's Earnings Per Share (TTM)?

The Boston Scientific EPS (TTM) is 2.38.

When Is the Next Boston Scientific Earnings Date?

Boston Scientific will release its next earnings report on 03-02-2027.

From a Technical Analysis Perspective, Is BSX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

What Stock Exchange Does Boston Scientific Trade On?

Boston Scientific is listed and trades on the New York Stock Exchange.

What Is the Stock Symbol for Boston Scientific?

The stock symbol for Boston Scientific is "BSX."

How Many Times Has Boston Scientific Stock Split?

Boston Scientific has split 2 times.

How Many Employees Does Boston Scientific Have?

Boston Scientific has 59000 employees.

What Is the BSX Premarket Price?

BSX's last pre-market stock price is 43.75. The pre-market share volume is 14,450.00, and the stock has changed by -0.57, or -1.29%.

What Is the BSX After Hours Price?

BSX's last after hours stock price is 40.19, the stock has changed by -3.31, or -7.61%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.